BioPharma

Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China

admin December 9, 2025

Fresh off the acquisition of metabolic medicines developer Metsera, Pfizer is again turning to dealmaking to expand its obesity drug pipeline, this time picking up an experimental oral ...

alpha-1 antitrypsin-associated liver disease

Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder

admin December 2, 2025

Regeneron Pharmaceuticals is committing $150 million to begin an alliance on a Tessera Therapeutics gene-editing medicine nearing the clinic as a potential treatment for a rare disease ...